Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience

Salman Khan, Clara Fischman, Shirish Huprikar

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Renal transplant recipients (RTR) who are seropositive for CMV (R+) are considered to be at intermediate risk for CMV disease. Current guidelines recommend high-dose valganciclovir (VGCV) prophylaxis because of limited data on the efficacy of low-dose VGCV. We describe our experience with using low-dose VGCV in R+ RTR. We retrospectively reviewed a cohort of 316 R+ RTR at our institution between 2002 and 2006. The primary endpoint was CMV disease at 1 year post transplant. The incidence of CMV disease at 12 months after transplantation was only 3% (6/221) in the D+R+ and 4% (4/95) in the D−R+ RTR. Low-dose VGCV was effective at preventing CMV disease in intermediate-risk (R+) RTR.

Original languageEnglish
Article numbere12780
JournalTransplant Infectious Disease
Volume19
Issue number6
DOIs
StatePublished - Dec 2017

Keywords

  • CMV prophylaxis
  • low-dose valganciclovir recipient positive
  • renal transplant recipients

Fingerprint

Dive into the research topics of 'Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience'. Together they form a unique fingerprint.

Cite this